Combating antimicrobial resistance: the silent war.

Autor:	Bo L; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States., Sun H; Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China., Li YD; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States., Zhu J; Carle Place Middle and High School, Carle Place, NY, United States., Wurpel JND; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States., Lin H; Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China., Chen ZS; Institute for Biotechnology, St. John's University, Queens, NY, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2024 Feb 14; Vol. 15, pp. 1347750. Date of Electronic Publication: 2024 Feb 14 (Print Publication: 2024).
DOI:	10.3389/fphar.2024.1347750
Abstrakt:	Once hailed as miraculous solutions, antibiotics no longer hold that status. The excessive use of antibiotics across human healthcare, agriculture, and animal husbandry has given rise to a broad array of multidrug-resistant (MDR) pathogens, posing formidable treatment challenges. Antimicrobial resistance (AMR) has evolved into a pressing global health crisis, linked to elevated mortality rates in the modern medical era. Additionally, the absence of effective antibiotics introduces substantial risks to medical and surgical procedures. The dwindling interest of pharmaceutical industries in developing new antibiotics against MDR pathogens has aggravated the scarcity issue, resulting in an exceedingly limited pipeline of new antibiotics. Given these circumstances, the imperative to devise novel strategies to combat perilous MDR pathogens has become paramount. Contemporary research has unveiled several promising avenues for addressing this challenge. The article provides a comprehensive overview of these innovative therapeutic approaches, highlighting their mechanisms of action, benefits, and drawbacks. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Bo, Sun, Li, Zhu, Wurpel, Lin and Chen.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu